Pharma News
29 Mar 2026 to 04 Apr 2026
Apr 4, 2026
India needs to transition from being a low-cost pharmaceutical manufacturer to a leader in global quality standards... - The Tribune
India's Commerce Secretary Rajesh Agrawal urged the pharmaceutical industry to enhance its global reputation by focusing on quality alongside cost-effectiveness. Speaking at the 'Chintan Shivir - Scaling Up Pharma Exports' event, he emphasized the need for innovation in biologics and biosimilars, aiming for India to lead in global pharmaceutical developments and strengthen its resilience in the market.
Apr 4, 2026
Mounjaro researcher: Support our obesity treatments or dangerous alternatives will proliferate - The Times
Eli Lilly's chief scientific officer, Daniel Skovronsky, criticized UK policies for driving consumers towards counterfeit weight-loss drugs, including Mounjaro. He urged the government to improve access to legitimate medications to combat this issue. Meanwhile, Novo Nordisk, maker of Ozempic and Wegovy, is also addressing counterfeit concerns. The UK’s MHRA reported significant seizures of illegal weight-loss drugs, highlighting public health risks.
Apr 4, 2026
Prices of Ozempic and Wegovy decrease in India - ARY News
Novo Nordisk has reduced prices for its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 48% in India to compete with local generics. The price cuts follow the expiration of the semaglutide patent, with Ozempic now starting at 1,415 rupees and Wegovy at 2,025 rupees. The move aims to maintain market share against competitors like Eli Lilly's Mounjaro.
Apr 4, 2026
Delhi Police dismantles operation redirecting government-provided medications for unauthorized sales; three individuals arrested.
Delhi Police has dismantled a racket involving the diversion of government-supplied medicines intended for free distribution to hospitals, which were being sold privately. Three individuals, Neeraj Kumar, Sushil, and Laxman Mukhia, have been arrested in connection with this illegal operation.
Apr 4, 2026
Intas Pharma Obtains 5-Year Exemption from NPPA Price Regulations for Patented Clozapine ER Capsules
The National Pharmaceutical Pricing Authority (NPPA) has granted Intas Pharmaceuticals Limited a five-year exemption from price control for its patented "Clozapine Extended Release Capsules" (12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg). This exemption is effective from the start of commercial production or patent expiry, whichever comes first, following an application from Intas.
Apr 4, 2026
Delhi Police Uncovers Counterfeit Sensodyne Toothpaste Manufacturing Operation in Khanjawala, Leading to One Arrest
Delhi Police's Crime Branch has dismantled a counterfeit Sensodyne toothpaste factory in Khanjawala, arresting one individual. The raid resulted in the seizure of thousands of fake toothpaste tubes, along with filling machinery and raw materials, highlighting ongoing efforts to combat counterfeit consumer products.
Apr 4, 2026
GTRI Reports That US Tariffs on Patented Medications Will Have Minimal Effect on India
India is unlikely to be significantly affected by the US's new 100% tariffs on certain patented drugs, as its exports mainly consist of low-cost generics, which are currently exempt. However, Indian firms producing branded drugs may face challenges. The tariffs stem from a broader US trade strategy citing national security concerns over foreign drug reliance.
Apr 4, 2026
Indian Court Grants Approval for Dr. Reddy's to Market Diabetes Medication Inventory
The Delhi High Court ruled in favor of public health in a trademark dispute between Novo Nordisk and Dr. Reddy's Laboratories over diabetes drugs. While upholding Novo Nordisk's 'Ozempic' trademark, the court allowed Dr. Reddy's to sell its 'OLYMVIQ' stock for 30 days and donate unsold inventory, emphasizing the need for accessible healthcare amid rising competition in the diabetes market.
Apr 4, 2026
Commerce Secretary urges pharmaceutical industry to lessen reliance on imported raw materials.
Commerce Secretary Rajesh Agrawal urged the Indian pharmaceutical industry to reduce reliance on imported raw materials and enhance export supply chains. He emphasized self-reliance in meeting domestic needs, aiming for 80-90% indigenous production. Agrawal highlighted the importance of quality, innovation, and transitioning to a value-driven industry, as India remains a key global player in pharmaceuticals with $30.47 billion in exports for 2024-25.
Apr 4, 2026
Trump's complete tariff on patented medications and their components might not have an immediate significant effect.
The US President Donald J. Trump has announced a 100% tariff on patented pharmaceuticals and their ingredients, effective in 120-180 days. While Indian firms like Sun Pharma may face short-term impacts, experts suggest limited effects overall, as 90% of India's pharma exports to the US are generics. The decision aims to address national security concerns regarding pharmaceutical imports.
Apr 4, 2026
Rajasthan Drug Control Authorities Confiscate Counterfeit Antibiotics Valued at ₹4 Lakh, Reports DrugsControl Media Services
The Rajasthan Drug Control Department has confiscated counterfeit antibiotics worth over ₹4 lakh after laboratory tests confirmed that the batch of QCE POD 20 lacked its active ingredient. The operation highlights ongoing efforts to combat the distribution of fake pharmaceuticals in the region.
Apr 4, 2026
Himachal High Court Rules That Not All Pharmaceutical Directors Are Responsible for Drug Quality Issues
The Himachal Pradesh High Court ruled that not all directors of pharmaceutical companies can be held criminally liable for the quality of drugs produced. This landmark decision clarifies corporate responsibility in the sector, emphasizing that liability for sub-standard drugs is not automatic for every director.
Apr 3, 2026
Trump reinstates pharmaceutical tariffs at 100%, but includes exemptions - BioPharma Dive
The Trump administration has reinstated 100% tariffs on imported pharmaceuticals to boost domestic production, exempting drugs from countries with trade deals and generics. Major drugmakers, including those investing $400 billion in U.S. facilities, benefit from these exemptions. However, mid-sized companies face potential challenges, prompting lobbying efforts against the tariffs. The policy's future remains uncertain beyond January 2029.
Apr 3, 2026
US imposes full 100% tariff on patented pharmaceuticals; minimal effect on India - The Indian Express
The US announced a 100% tariff on imported patented pharmaceuticals and associated ingredients, effective July 31, citing national security concerns over reliance on imports. President Trump stated that generic drugs are exempt for now, but future adjustments may occur. India, a major exporter of generics, is also boosting patented drug production.
Apr 3, 2026
Novartis AG (ADR) Shares: A Robust Pharmaceutical Company with Solid Fundamentals and Growth Potential
Novartis AG (ADR) continues to be a leader in the pharmaceutical sector, offering North American investors exposure to innovative therapies in oncology, immunology, and cardiovascular health. With a robust pipeline and blockbuster drugs like Entresto, Cosentyx, and Kymriah, Novartis emphasizes research-driven innovation and strategic acquisitions, positioning itself for sustained growth amid evolving market dynamics.
Apr 3, 2026
Is India's pharmaceutical industry prepared for upcoming patent expirations?
The Indian pharmaceutical industry is poised for significant growth as a wave of blockbuster drugs, including pembrolizumab and apixaban, face patent expirations between 2026 and 2032. Companies like Biocon and Zydus Lifesciences are focusing on biosimilars and complex generics, leveraging their manufacturing capabilities to enhance global access to affordable therapies. This strategic shift marks a critical inflection point for the sector.
Apr 3, 2026
Merck & Co., Inc. shares: A fundamental player in drug development and a dependable source of dividends for investors.
Merck & Co., Inc. continues to thrive in the biopharmaceutical sector, driven by blockbuster drugs like Keytruda and Gardasil. The company maintains strong revenue from oncology, vaccines, and diabetes treatments, appealing to North American investors seeking stability. With a robust R&D pipeline and a commitment to dividends, Merck is well-positioned despite potential risks from patent expirations and competition.
Apr 3, 2026
Novo Nordisk Implements Bold Pricing Approach for Wegovy During Company Restructuring
Novo Nordisk has launched a $249/month subscription for its weight-loss drug Wegovy to enhance patient loyalty and compete with Eli Lilly. Concurrently, the company will cut 400 jobs at its Indiana manufacturing facility as part of a global restructuring plan aimed at reducing costs by $1.3 billion and strengthening its diabetes and obesity divisions.
Apr 3, 2026
Regeneron Pharmaceuticals: The Research Powerhouse Undergoing a Critical Transition
Regeneron Pharmaceuticals, Inc. is navigating a pivotal transition in 2026, focusing on oncology and obesity markets while maintaining strong performance in immunology with drugs like Dupixent and Eylea HD. Despite facing competition and regulatory challenges, the company’s innovative R&D model and strategic partnerships position it for future growth. Investors are optimistic about upcoming data on Fianlimab and the COPD market.
Apr 3, 2026
Overview of Pricing and Availability for Novo and Lilly's Weight Loss Medications - AOL.com
The FDA has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, marking its entry into the obesity treatment market. Foundayo will be available in the U.S. starting April 6, 2026, with pricing starting at $149 per month. This follows Novo Nordisk's launch of its oral Wegovy in January 2026.
Apr 3, 2026
Regeneron Pharmaceuticals: A Biotech Leader Facing Tariff Challenges? - Ad-hoc-news.de
Regeneron Pharmaceuticals faces potential challenges from new US tariffs on imported drugs, which could impact its supply chain and margins. However, the company, known for blockbuster drugs like Eylea and Dupixent, may benefit from domestic production incentives. Analysts remain optimistic about Regeneron's strong pipeline and market position, suggesting it could be a strategic buy for North American investors.
Apr 3, 2026
Eli Lilly and Company shares: Foundayo approval sparks potential surge in 2026? - Ad-hoc-news.de
Eli Lilly's oral weight-loss pill, Foundayo (orforglipron), has received FDA approval and is set to launch on April 6, 2026. This once-daily medication aims to capture a significant share of the $100 billion obesity market, challenging competitors like Novo Nordisk. Analysts project Foundayo could generate sales between $1.5 billion and $2.8 billion in 2026, enhancing Eli Lilly's growth potential.
Apr 3, 2026
Trump enacts a full 100% tariff on imported patented medications and updates metal tariffs.
The U.S. has implemented a 100% tariff on patented pharmaceutical imports from countries like India that lack reshoring agreements, as announced by President Trump. Generic medicines are currently exempt, but this may change. The new tariffs take effect on July 31 for larger companies and September 29 for smaller ones, alongside revised tariffs on metals.
Apr 3, 2026
Government provides tailored support to alleviate pressure on pharmaceutical and medical technology producers.
The Centre has announced customs duty exemptions on 40 petrochemical inputs to alleviate cost burdens for pharmaceutical and medtech manufacturers in West Asia. This initiative aims to support the strained supply chains in these sectors, providing much-needed relief to the industry.
Apr 3, 2026
No Resolution Found for the Escalating Problem of Counterfeit Medications and NDPS-Related Concerns in India
A Nigerian innovator, Ini-Mfon Udofia, has introduced a blockchain-based solution through Medichain NG to tackle counterfeit and substandard medicines. This development highlights the pressing need for similar technological advancements in India to address the growing crisis of fake medicines and NDPS-related issues.
Apr 3, 2026
GTRI Study Shows India Protected from US Drug Tariffs - Rediff Money
India is largely shielded from US President Trump's 100% tariffs on certain patented drugs, according to the Global Trade Research Initiative (GTRI). The country primarily exports low-cost generics, which make up over 90% of US drug use. However, Indian firms producing branded drugs may face tariff pressure, raising concerns about future uncertainties if tariffs extend to generics.
Apr 3, 2026
Trump Implements Full Tariff on Patented Brand-Name Medications to Bring Manufacturing Back to the U.S.
President Donald Trump has signed a proclamation imposing up to 100% tariffs on imported patented brand-name drugs and their active pharmaceutical ingredients (APIs) to reshore manufacturing and reduce U.S. prices. This move is made under Section 232 of the Trade Expansion Act, citing national security concerns.
Apr 3, 2026
Trump Issues Ultimatum: Import Drugs with Full Tariff or Relocate to the USA - The420.in
President Trump has imposed 100% tariffs on branded and patented drug imports to encourage U.S. manufacturing and price cuts, exempting India's generic exports. Companies can opt for a 20% tariff during U.S. plant construction. Compliance deadlines are set for large and small producers, while trade allies like the EU and Japan receive tariff caps. This policy aims to revitalize American manufacturing.
Apr 3, 2026
Health professionals express worries about the growing availability and misuse of a widely-used weight-loss medication.
India's weight-loss drug market is set to transform following the expiration of the semaglutide patent held by Novo Nordisk on March 20, 2026. Generic versions of Wegovy, the popular weight-loss injection, are now available at about a quarter of the original price, improving access to this effective anti-obesity medication amid rising obesity rates in the country.
Apr 3, 2026
US Imposes 100% Tariff on Patented Medications; Generics Currently Excluded
The US has imposed a 100% duty on imported patented pharmaceuticals and associated ingredients, while exempting generic drugs. This decision, announced by President Donald Trump, aims to address national security concerns. Indian pharmaceutical exports, primarily generics, remain unaffected for now, but future tariffs could impact branded drug producers. The tariffs are set to begin between August and September 2026.
Apr 3, 2026
U.S. Imposes 100% Tariff on Patented Medications, While Generic Drugs Are Excluded.
The US has imposed a 100% duty on imported patented pharmaceuticals and associated ingredients, as stated by President Donald Trump. Generic drugs are currently exempt from this duty, benefiting Indian pharmaceutical companies. However, concerns arise that increased patent evergreening may reduce the availability of off-patented drugs in the future.
Apr 3, 2026
A New Chapter in U.S. Drug Pricing: Transitioning from Policy Changes to Strategic Adjustments
The U.S. pharmaceutical market is undergoing significant changes due to the Inflation Reduction Act and the TrumpRx platform, which aim to lower drug prices. Notable drugs like Eliquis, Jardiance, and Januvia will see price reductions of 38%-60% starting January 2026. The landscape is shifting towards price negotiation and transparency, challenging traditional pricing strategies in the industry.
Apr 3, 2026
Increase in generic weight-loss medications sparks price competition in India - The Globe and Mail
India is set to launch over 50 low-cost generic GLP-1 drugs, including versions of Novo Nordisk's Ozempic and Wegovy, following patent expirations. Prices are expected to drop by 60-90%, prompting concerns over misuse and malpractice. The Drugs Controller General of India is enforcing strict regulations to prevent unauthorized sales, emphasizing that these medications should only be prescribed by specialists.
Apr 2, 2026
US grants approval for Eli Lilly's GLP-1 pill Foundayo, marking a new development in the weight-loss medication sector.
The US FDA has approved Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), enhancing competition with Novo Nordisk's injectable therapies like Wegovy. Set to launch on April 6, Foundayo offers a convenient daily pill option, potentially expanding the GLP-1 market. Priced at $149 per month, it aims to address obesity treatment's shift towards pharmacological management.
Apr 2, 2026
Biocad patent reveals new antibody-drug conjugates - BioWorld
Biocad Ltd. has announced a new patent for antibody-drug conjugates that combine antibodies with cytotoxic drugs via linkers, aimed at enhancing cancer treatment.
Apr 2, 2026
India Has the Capability to Produce Any Medication. What Is Required to Develop a Novel Molecule? - The Core
Novo Nordisk's Indian patent on semaglutide expired, leading to a rapid influx of over sixteen generic versions of Ozempic, causing prices to plummet by 70-90%. Indian firms like Zydus, Sun Pharma, and Mankind Pharma are now focusing on original drug development, with candidates like MKP10241 and Utreglutide targeting obesity, marking a shift towards innovation in the Indian pharma industry.
Apr 2, 2026
High Court's 'Skinny Label' Case Could Address Broader Issues - Food and Drug Regulations
The U.S. Supreme Court has agreed to hear Hikma Pharmaceuticals' appeal in the case against Amarin Pharma regarding induced patent infringement related to the omega-3 drug Vascepa. The case will clarify the extent of inducement liability under Section 271(b) when a generic drug omits patented uses from its label but markets itself as a generic version.
Apr 2, 2026
Overview of Pricing and Availability for Novo and Lilly's Weight Loss Medications | WKZO
The FDA has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, marking its entry into the obesity treatment market. Foundayo will be available in the U.S. starting April 6, with self-pay prices beginning at $149 per month. This follows Novo Nordisk's launch of its oral Wegovy in January 2026.
Apr 2, 2026
Recently authorized weight-loss medications may increase availability of GLP-1 treatments - PhillyVoice
Eli Lilly's GLP-1 oral medication, Foundayo, has received FDA approval, becoming the second weight-loss pill after Novo Nordisk's Wegovy. While both medications show promise for obesity treatment, affordability remains a concern, with out-of-pocket costs potentially reaching several hundred dollars monthly. Experts emphasize the need for clearer insurance coverage and pricing strategies to improve access for patients.
Apr 2, 2026
Forecast: Eli Lilly's Upcoming Billion-Dollar Revenue Source Will Surprise You. (Clue: It's Not Related to Weight Loss Medications.)
Eli Lilly (NYSE: LLY) is gaining investor interest due to its successful weight loss drugs, Mounjaro and Zepbound, which generated $11 billion in revenue last quarter. The company recently received regulatory approval for Foundayo (orforglipron) and is investing in AI partnerships, including a $2 billion deal with Insilico Medicine, to enhance drug discovery and development processes.
Apr 2, 2026
Rajya Sabha Erupts Over Significant Differences in Medicine Prices; Calls for Stronger Regulations
The Rajya Sabha erupted in protest on April 1, 2026, over significant disparities in medicine prices among different brands, despite identical active ingredients. Members called for stringent legislation to address these pricing inequalities, highlighting the urgent need for regulatory reforms in the pharmaceutical sector.
Apr 2, 2026
Emcure reduces the cost of its semaglutide weight loss medication, Poviztra, by 50% following the expiration of Novo Nordisk's patent.
Emcure Pharmaceuticals has reduced the price of its weight management drug Poviztra, a semaglutide injection, from ₹8,790 to ₹3,999 per month, effective April 3, 2026. This price cut follows the loss of patent protection for semaglutide in India, prompting increased competition and affordability in obesity treatment. CEO Satish Mehta emphasized the importance of making these therapies accessible to more patients.
Apr 2, 2026
Eli Lilly Explores AI-Enhanced Opportunities in Drug Development | Intellectia.AI
Morgan Stanley has maintained an Overweight rating and a $1,313 price target on Eli Lilly (LLY) following the FDA's approval of Foundayo, a daily oral GLP-1 for chronic weight management. This approval aligns with expectations and positions Eli Lilly competitively against Novo Nordisk (NVO), which recently launched oral Wegovy. Foundayo offers a clean label without food or water restrictions.
Apr 2, 2026
Eli Lilly's weight loss medication Foundayo receives approval from the FDA - NPR
The FDA has approved Eli Lilly's new obesity pill, Foundayo, which offers a convenient alternative to injectable GLP-1 medications like Zepbound. Foundayo contains the new ingredient Orforglipron and is expected to appeal to those hesitant about injections. Priced at $149 monthly, it is cheaper than Zepbound and may be available for as low as $25 with insurance.
Apr 2, 2026
US Drug Pricing Strategies Expected to Overlook Indian Generics, Sun Pharma Impacted Less
US drug pricing policies are expected to primarily target patented medicines, sparing Indian generics, according to Systematix Group's Vishal Manchanda. Sun Pharmaceutical Industries may need pricing agreements due to its specialty drug exposure, but any financial impact is projected to be limited to 2-3% EBITDA reduction. Generics remain crucial to healthcare, making them less vulnerable to tariffs.
Apr 2, 2026
The Trump administration is getting ready to impose tariffs of up to 100% on certain imported medications.
The Trump administration has introduced new tariffs on branded drugs from pharmaceutical companies that haven't negotiated U.S. drug price reductions. A 100% tariff will apply to patented medications, while companies onshoring production face a 20% tariff, increasing to 100% in four years. Exemptions exist for firms negotiating with Health and Human Services.
Apr 2, 2026
Is Sun Pharma Also Secure? US Drug Pricing Regulations Will Not Significantly Impact Indian Generics!
Analysts from Systematix Group have indicated that new US drug pricing rules will not significantly impact Indian generics, including Sun Pharma. The focus of these rules is on patented medicines, leaving generics largely unaffected. Sun Pharma's shift towards branded products and reduced reliance on US generics positions it favorably, with potential financial impacts limited to 2-3% EBITDA.
Apr 2, 2026
Argentina Withdraws Important Patent Guidelines, Endangering Citizens' Access To ...
Argentina has revoked key patentability guidelines in its pharmaceutical sector, risking access to affordable medical tools and enabling monopolies. This shift contradicts the World Trade Organization’s TRIPS Agreement, which supports public health needs. Médecins Sans Frontières warns that this could delay treatment and increase costs, urging policymakers to restore the guidelines to ensure competition and access to healthcare.
Apr 2, 2026
Oral GLP-1 Medication, Weekly Insulin Injections, High-Dose SMA Treatment, and Ovarian Cancer Therapy
The FDA has approved several breakthrough treatments, including an oral GLP-1 pill for obesity and type 2 diabetes, a once-weekly insulin, a high-dose therapy for spinal muscular atrophy (SMA), and a new treatment for platinum-resistant ovarian cancer. These approvals enhance therapeutic options for patients in these critical areas.
Apr 2, 2026
The Impact of India's Trade Agreements on the Cost of Affordable Medications | The India Forum
India's recent free trade agreements (FTAs) may undermine the World Trade Organization's TRIPS flexibilities, potentially raising medicine prices and limiting access to affordable healthcare. The shift towards voluntary licensing over compulsory licensing, as seen in the India-UK Comprehensive Economic and Trade Agreement (CETA), raises concerns about the influence of big pharma on India's patent policies and transparency in drug pricing.
Apr 2, 2026
Government Releases Guidelines on GLP-1 Medications: Usage, Risks, and Regulatory Framework
The Government of India has released national guidelines on GLP-1 receptor agonist drugs to address unauthorized sales, unsupervised use, and misleading promotions. These guidelines aim to ensure safe usage and regulation of GLP-1 drugs, enhancing public health and safety.
Apr 2, 2026
Impending price competition emerges in China's rapidly growing weight-loss medication sector - Chinadaily.com.cn
China's GLP-1 weight-loss drug market is set for disruption as the patent for Novo Nordisk's semaglutide expires, allowing domestic companies to launch generics. Prices for semaglutide have halved, while tirzepatide's costs have dropped over 80%. With rising obesity rates and a potential $150 billion market, competition is intensifying among players like Innovent Biologics' mazdutide.
Apr 1, 2026
India's GLP-1 market intensifies as Novo Nordisk lowers prices for diabetes and obesity medications.
Novo Nordisk has significantly reduced prices for its drugs Ozempic and Wegovy in India, cutting Ozempic by 36% and Wegovy by 48% effective April 1. This move responds to competition from low-cost generic semaglutide versions following patent expirations. The new prices aim to enhance access to diabetes and obesity treatments while maintaining a premium market position.
Apr 1, 2026
The Availability of Ozempic in a Free Market Will Significantly Impact Millions of Individuals
Ozempic, a diabetes and obesity treatment, is set to become available as a generic in India, China, and other countries, potentially reducing its price from $300 to as low as $3. The article highlights the disparity in drug pricing due to patent monopolies, emphasizing the need for a debate on alternative funding for drug research to improve accessibility.
Apr 1, 2026
Indian Legislation Allows Access to Cost-Effective Generic Medications While Respecting Patent Rights
India's patent regime allows domestic manufacturers to produce affordable generic medicines without infringing on patents, ensuring a balance between intellectual property rights and public health. This legal framework supports the availability of high-quality medications for the population.
Apr 1, 2026
Dosell AB Receives European Patent for Data-Driven Medication Management Solutions
iZafe Group AB's subsidiary, Dosell AB, has received a European patent (EP4228584) for its "Medication Delivery" system, enhancing its position in personalized healthcare. The patent focuses on analyzing patient data to optimize medication treatment, aligning with iZafe's strategy of integrating medical technology and AI. CEO Anders Segerström emphasized its importance for future healthcare solutions.
Apr 1, 2026
Indian Authorities Enhance Monitoring of GLP-1 Weight-Loss Medications Amid Surge of Generic Versions
India's drug regulator has ramped up surveillance of GLP-1 weight loss drugs, particularly after the patent expiry of semaglutide, leading to over 40 generics flooding the market. Audits at 49 entities revealed concerns over unauthorized sales. Prices have plummeted, raising fears of unsupervised use. The market for GLP-1 therapies is projected to grow significantly, with strict regulations enforced to ensure safety.
Apr 1, 2026
Dosell AB Receives European Patent for Data-Driven Medication Management - TradingView
iZafe Group AB's subsidiary, Dosell AB, has received a European patent (EP4228584) for its "Medication Delivery" system, enhancing its position in personalized healthcare. The patent allows for the analysis of patient data to optimize medication treatment over time. CEO Anders Segerström emphasized its importance for future data-driven healthcare solutions and intellectual property value.
Apr 1, 2026
NPPA grants a five-year exemption from DPCO for Intas Pharma's patented antipsychotic formulation.
The National Pharmaceutical Pricing Authority (NPPA) has exempted Intas Pharmaceuticals' clozapine extended release capsules (12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg) from price control for five years, based on a patent claim. This decision follows a review by the Multidisciplinary Committee of Experts and is contingent on the company's compliance with pricing regulations post-exemption.
Apr 1, 2026
Exploring Eli Lilly's $7.8 Billion Purchase of Centessa Pharmaceuticals: The Orexin Boom
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, focusing on the development of cleminorexton (ORX750), a promising treatment for narcolepsy and idiopathic hypersomnia. This acquisition highlights the competitive landscape in the orexin market, positioning Lilly to enhance its neuroscience portfolio.
Apr 1, 2026
Curocell approaches a significant achievement with South Korea's first domestically developed CAR-T cancer treatment.
Curocell Inc., a South Korean biotech firm, plans to seek approval for its CAR-T treatment, Anbal-cel, for diffuse large B-cell lymphoma by September 2025. The company aims to localize the blood cancer drug to enhance accessibility and treatment options for patients.
Apr 1, 2026
The New Blue-Chip: How Johnson & Johnson Transformed Its Business for Future Growth
Johnson & Johnson (NYSE: JNJ) has transformed into a focused healthcare powerhouse, shedding its consumer health business and emphasizing Innovative Medicine and MedTech. Under CEO Joaquin Duato, J&J aims for high-margin medical breakthroughs, with a projected revenue exceeding $100 billion in 2026. Key products include Darzalex and the upcoming Icotrokinra. Despite ongoing talc litigation, J&J's strong financials and strategic acquisitions position it for future growth.
Apr 1, 2026
Overview of Pricing and Availability for Novo and Lilly's Weight Loss Medications - Yahoo! Finance Canada
The FDA has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, marking its entry into the obesity treatment market. Foundayo will be available in the U.S. starting April 6, with self-pay prices beginning at $149 per month. This follows Novo Nordisk's launch of its oral Wegovy in January 2026, intensifying competition in the sector.
Apr 1, 2026
Novo Nordisk reduces prices of Ozempic and Wegovy in India once more to compete with lower-cost generics.
Novo Nordisk has reduced prices for its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 48% in India to compete with local generics. The price cuts follow the expiration of the patent on semaglutide, the active ingredient. The new prices aim to maintain market share against competitors like Dr Reddy's and Eli Lilly's Mounjaro.
Apr 1, 2026
Lilly's obesity medication receives approval in the United States - The Detroit News
The FDA has approved Eli Lilly's weight-loss pill, orforglipron, branded as Foundayo, which targets the appetite-suppressing GLP-1 hormone. Set to launch on April 6 at $149 per month, it offers a convenient alternative to Novo Nordisk's Wegovy. In trials, orforglipron helped users lose 12-15% of body weight, though it carries a warning for thyroid tumors.
Apr 1, 2026
Novo Nordisk's Ozempic and Wegovy in India: Major Price Reduction Ahead! 48% Discount, Will Generics Follow?
Novo Nordisk announced a significant price reduction of up to 48% for its drugs Ozempic and Wegovy in India, effective April 1, 2026, due to the impending launch of cheaper generics following patent expiry. Competitors like Sun Pharma and Dr. Reddy's Laboratories are preparing to introduce their versions, increasing market competition and impacting Novo Nordisk's profit outlook.
Apr 1, 2026
Novo Nordisk Reduces Prices in India in Response to Surge of Generic Competitors - Whalesbook
Novo Nordisk India is reducing prices for its diabetes and weight-loss drugs, Ozempic and Wegovy, by 36% and 48%, respectively, starting April 1, 2026. This move follows the expiration of its Indian patent for semaglutide, prompting competition from generics. The company aims to maintain market share amid rising competition, with the GLP-1 market projected to grow significantly by 2030.
Apr 1, 2026
Prices of Ozempic and Wegovy Reduced Once More in India to Compete with Lower-Cost Generics
Apr 1, 2026
Mint Analysis: Implications of the weight-loss medication craze for the pharmaceutical industry and for individuals
A Pharmarack report from February 2026 highlights that despite decreasing drug prices, the eligible patient pool remains unchanged. It suggests that patients and doctors may continue to favor innovator brands due to established efficacy and safety profiles, particularly among those who can afford them.
Mar 31, 2026
Novo reduces semaglutide prices in response to the introduction of generics in India - BusinessToday
Novo Nordisk has announced price cuts of up to 48% for its diabetes and obesity drugs, Ozempic and Wegovy, in India, following the expiration of semaglutide's patent. The reductions aim to enhance patient access amid rising competition from generics. Novo Nordisk is also partnering with Emcure Pharmaceuticals and Abbott India to improve distribution and ensure proper usage of semaglutide.
Mar 31, 2026
How Indian legislation facilitates the production of affordable medicines while adhering to patent regulations
On March 20, 2026, Novo Nordisk's patent on semaglutide, the active ingredient in Ozempic and Wegovy, expired in India, prompting over 40 Indian companies, including Natco Pharma, to launch generics at ₹1,290 per month, significantly lower than the U.S. price of $936. This highlights India's legal framework supporting affordable healthcare over patent rights, setting a precedent for other developing nations.
Mar 31, 2026
Patient vs. Patent: The Role of Indian Legislation in Facilitating Cost-Effective Medicine Manufacturing Without...
India's Patents Act, particularly Sections 84 to 92, facilitates compulsory licensing to ensure public access to medicines. Section 3(d) prevents "evergreening," limiting companies like Novo Nordisk from extending patent protections on semaglutide. This framework supports public interest during health crises and allows for the export of patented drugs to countries with insufficient manufacturing capacity.
Mar 31, 2026
Acurx Pharma secures a patent in South Korea for its DNA Polymerase IIIC inhibitors - Pharmabiz.com
Acurx Pharmaceuticals, Inc. has received a new patent from the Korean Intellectual Property Office for DNA Polymerase IIIC inhibitors, enhancing its intellectual property portfolio. The company’s lead drug, ibezapolstat, is set to enter phase 3 trials for treating acute C. difficile infection. Acurx aims to revolutionize treatment for serious bacterial infections with its innovative antibiotic candidates.
Mar 31, 2026
Prices for weight-loss and diabetes medications Ozempic and Wegovy reduced by as much as 48%.
Novo Nordisk has announced a price reduction for its semaglutide-based therapies, Ozempic and Wegovy, in India, effective April 1, 2026. Ozempic's price will drop by 36%, while Wegovy's will decrease by 48%, making the weekly cost Rs. 1,415 for both. This initiative aims to enhance accessibility for patients managing type 2 diabetes and obesity.
Mar 31, 2026
Consumer Advocacy Group Calls on HHS to Bypass Patents Amid U.S. Hold on Semaglutide Generics
Generic versions of semaglutide are set to launch globally at lower prices, but U.S. patients may wait until 2032 for the drug to go off-patent. This delay raises concerns about patent protections and access to generics, prompting a consumer group to urge HHS to intervene using a rarely utilized government authority.
Mar 31, 2026
Exploring India's Anti-Obesity Drug Market: Current Options and Future Developments Beyond Ozempic
India's semaglutide market has expanded significantly following the loss of patent protection for Novo Nordisk's drugs Ozempic and Wegovy. Domestic companies like Sun Pharma, Dr Reddy’s, and Glenmark have launched affordable generics, reducing monthly costs from thousands to as low as Rs 1,290. This shift enhances access to diabetes and obesity treatments, with more options and innovative therapies on the horizon.
Mar 31, 2026
Biogen Secures Two Rapidly Expanding Medications in Major Agreement with Apellis - Benzinga
Biogen has acquired Apellis Pharmaceuticals to enhance its portfolio in immunology and rare diseases, adding FDA-approved therapies Empaveli and Syfovre. The deal, which includes contingent value rights, is expected to boost Biogen's revenue growth and adjusted earnings per share starting in 2027. Apellis shares surged 136.16% to $40.36, while Biogen's shares fell 4.60% to $178.94.
Mar 31, 2026
India's GLP-1 Market Conflict: Patent Expiration Triggers Price Competition | Whalesbook
India's GLP-1 drug market is poised for significant growth, projected to reach ₹5,000 crore by 2030 following the expiration of the Semaglutide patent. Companies like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Emcure Pharmaceuticals are adopting diverse strategies amid intense price competition. Analysts are divided, with some downgrading firms reliant on GLP-1 sales while others maintain 'Buy' ratings for Sun Pharma and Emcure.
Mar 31, 2026
USPTO event includes discussions on the significance of PTAB for patents in the life sciences sector | MLex
At a recent US Patent and Trademark Office event, pharmaceutical industry advocates argued that inter partes review challenges at the Patent Trial and Appeal Board are unnecessary, while generic and biosimilar representatives defended the board as essential for drug access and market competition. The discussion highlighted ongoing tensions in patent challenges within the life sciences sector.
Mar 31, 2026
Novo Nordisk reduces the price of Ozempic in India in response to the rise of generic alternatives - HT Syndication
Novo Nordisk AS has reduced prices for its weight-loss drugs Ozempic and Wegovy in India, with the lowest doses now costing Rs.1,415 per weekly shot, down from Rs.2,200 and Rs.2,712. This price cut, effective April 1, follows the expiration of the patent for semaglutide, the active ingredient, allowing for increased competition.
Mar 31, 2026
Past revelations resurface to trouble CEO involved in major pharmaceuticals and gambling.
Former Contour Clinics CEO Mike Canizales is suing the company for damages and lost earnings after his dismissal in August 2025. He alleges financial irregularities and claims founder Dr. Josh Wall struggled with substance abuse and embezzlement, which Wall denies. The case highlights internal turmoil within the cosmetic clinic chain, valued at $160 million.
Mar 31, 2026
Lupin Challenges Merck! Generic Sugammadex Receives Tentative Approval from the US FDA
Lupin Limited has received tentative approval from the US FDA for its generic Sugammadex injection, challenging Merck & Co.'s Bridion. This approval positions Lupin to enter the $23.6 billion U.S. sterile injectable market, although it faces patent challenges from Merck. Analysts remain optimistic about both companies, with price targets indicating potential growth.
Mar 31, 2026
Delhi High Court Issues Permanent Ban on Intas's Use of 'Bevatas' Trademark, Supports Sun ...
The Delhi High Court has permanently restrained Intas Pharmaceuticals Ltd. from using the trademark "Bevatas," upholding Sun Pharma's trademark "Bevetex." This ruling addresses trademark infringement in the pharmaceutical sector, particularly concerning cancer treatment products.
Mar 31, 2026
Haryana requires real-time monitoring of medication in government hospitals.
The Haryana Government has mandated that all government hospitals implement real-time medicine tracking through a centralized portal. This initiative aims to enhance transparency in public healthcare and reduce the necessity for patients to purchase medications independently.
Mar 31, 2026
Wockhardt's Innovative Antibiotic Zaynich® (Zidebactam/Cefepime) Approved by CDSCO for ...
Wockhardt Limited's novel antibiotic Zaynich® (Zidebactam/Cefepime) has received approval from the Central Drugs Standard Control Organisation (CDSCO) for treating gram-negative infections. This breakthrough marks a significant advancement in antibiotic therapy.
Mar 30, 2026
The impact of GLP-1 medications and shifts in dietary patterns may affect the potato sector in P.E.I.
P.E.I. potato farmers face challenges as GLP-1 drugs, like Ozempic and Wegovy, reshape Canadian eating habits. A Dalhousie University survey reveals nearly 1.9 million Canadians use these medications, leading to decreased potato consumption and an estimated $3.3 billion in lost sales annually. Industry experts stress the need for innovation to promote potatoes' nutritional value amidst changing consumer preferences.
Mar 30, 2026
Authorities Conduct Raids Across Multiple States, Confiscating Thousands of Prohibited Cough Syrups and Narcotic Medications
Police in Rajasthan, Bihar, and Punjab conducted multi-state raids, seizing thousands of banned cough syrups and narcotic pills. The operations highlight a concerning increase in drug diversion activities across these regions.
Mar 30, 2026
Editas Medicine reveals that the USPTO has upheld its earlier ruling in support of the Broad Institute.
Editas Medicine, Inc. announced that the US Patent and Trademark Office reaffirmed the Broad Institute's inventorship priority for CRISPR/Cas9 gene editing in human cells. This decision follows a patent interference case involving the Broad Institute and the University of California. Editas continues to develop its gene editing therapies, including EDIT-401, which has shown significant LDL cholesterol reduction in non-human primates.
Mar 30, 2026
Identifying Counterfeit GLP-1 Medications in India: A Guide to Prevention - NDTV
GLP-1 drugs, particularly semaglutide, are in high demand for diabetes and weight loss in India, but counterfeit versions are emerging following patent expiry. Authorities are cracking down on illegal sales, while the WHO and FDA have warned about fake semaglutide. Novo Nordisk advises consumers to verify authenticity to avoid health risks associated with counterfeit medications.
Mar 30, 2026
Specialists discuss strategies for advancing biologics and mRNA at the Indian ...
Experts at the Indian Pharmaceutical Alliance webinar emphasized India's potential to lead in biologics and mRNA production, driven by expiring drug patents. They highlighted the importance of advanced biomanufacturing, AI-driven digitalization, and global partnerships, such as the UK–India Net Zero Innovation Partnership, to enhance efficiency and scalability in pharmaceutical manufacturing. The session also addressed the rising demand for mRNA and lipid nanoparticle delivery systems.
Mar 30, 2026
Lapsed patent in India leads to surge in affordable weight-loss medications - Yahoo Finance
Novo Nordisk's patent for semaglutide, the active ingredient in GLP-1 drugs Ozempic and Wegovy, has expired in India, leading to a surge of generic versions and a price drop of 70% to 90%. However, U.S. patients won't benefit soon, as Novo Nordisk's U.S. patents remain until the early 2030s.
Mar 30, 2026
Clearmind Medicine Reports Successful Conclusion of Treatment and Follow-Up for 18 Participants...
Clearmind Medicine Inc. (Nasdaq: CMND) has successfully completed treatment for 18 participants in its Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder (AUD). The trial, conducted at multiple prestigious institutions, has also added four new participants at its Tel Aviv site, indicating strong operational progress.
Mar 30, 2026
BioNxt Solutions Pursues Fast-Tracked US Patent for Essential Drug Delivery Innovation
BioNxt Solutions is advancing its global patent strategy by filing a fast-track application with the U.S. Patent and Trademark Office after securing a European patent for its oral film drug delivery technology. The lead product, BNT23001, targets Multiple Sclerosis and Myasthenia gravis. The company aims to establish partnerships in the neurology sector while navigating cautious investor sentiment.
Mar 30, 2026
Clearmind Medicine (Nasdaq: CMND) has finished administering treatment to 18 patients involved in the CMND-100 study.
Clearmind Medicine Inc. announced the successful completion of treatment and follow-up for 18 participants in its Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder. The trial, conducted at institutions like Yale and Johns Hopkins, has also added four more participants at its Tel Aviv site, indicating strong progress in the study.
Mar 30, 2026
Wockhardt Secures 5-Year Exemption from NPPA Price Regulation for Nafithromycin 400 mg Tablets
The National Pharmaceutical Pricing Authority (NPPA) has granted Wockhardt Limited a five-year exemption from price control for its patented "Nafithromycin Tablets" (400 mg) under the Drugs (Prices Control) Order, 2013. This exemption is effective from the start of commercial marketing or patent expiry. Wockhardt must inform NPPA of pricing details upon launch.
Mar 30, 2026
Novo Nordisk Reduces Ozempic Pricing in India to Compete with Generic Brands - Whalesbook
Novo Nordisk plans to reduce the price of its GLP-1 drug, Ozempic, in India by 30-50% to compete with generics from companies like Sun Pharma and Dr. Reddy's, which offer semaglutide at significantly lower prices. This strategy aims to maintain market share in India's growing diabetes treatment sector, despite potential risks to profit margins and brand value.
Mar 30, 2026
Indian Pharmaceutical Tycoons Invest Heavily in Generic Weight-Loss Medications, Leading to Increased Regulatory Oversight
The expiry of the patent for semaglutide, the active ingredient in Novo Nordisk's diabetes and obesity drugs, has led to the launch of low-cost generics by Indian pharma companies. Sun Pharmaceutical Industries introduced semaglutide pen injections under the brands Noveltreat and Sematrinity, priced at 3,600 and 3,000 rupees per month, respectively, significantly cheaper than Ozempic and Wegovy.
Mar 30, 2026
Coherus BioSciences Shares: Biosimilar Pioneer Shifts Focus to Oncology in Response to Market Challenges
Coherus BioSciences (NASDAQ: CHRS) is transitioning from a focus on biosimilars, like its Humira biosimilar Yusimry, to innovative oncology treatments. This strategic pivot aims to enhance long-term value amid rising cancer incidence and competition from major players like Amgen and Pfizer. Investors should monitor pipeline developments and market positioning as the company seeks to redefine its growth trajectory.
Mar 30, 2026
Guggenheim Increases AstraZeneca Price Forecast Prior to First Quarter Earnings Report - 24/7 Wall St.
AstraZeneca PLC (NASDAQ: AZN) reported FY2025 revenue of $58.74 billion, an 8% increase, driven by its oncology segment, particularly blockbuster drugs Tagrisso and Enhertu. Guggenheim raised its price target for AstraZeneca to 16,500 GBp, citing strong pipeline prospects and a dividend increase to $3.30 per share. The company anticipates mid-to-high single-digit revenue growth through 2026.
Mar 30, 2026
How Merck's Latest Cholesterol Treatment Aims to Make a Significant Impact by Eliminating Injections
Merck's experimental cholesterol drug, enlicitide, has shown superior performance compared to ezetimibe and bempedoic acid, according to recent findings. This positive outcome supports Merck's efforts to secure approval for enlicitide later this year, as all patients were also receiving standard statin therapy.
Mar 30, 2026
Could Positive Camzyos Results Enhance BMY's Cardiovascular Offerings? - Yahoo Finance
Bristol Myers Squibb (BMY) reported positive results from the SCOUT-HCM study for Camzyos (mavacamten) in adolescents with obstructive hypertrophic cardiomyopathy, showing significant LVOT gradient reduction. Camzyos, currently approved for adults, could expand its market. However, BMY discontinued the Librexia study for milvexian due to efficacy concerns, while competition increases with Cytokinetics' Myqorzo approval.
Mar 29, 2026
With the expiration of the Ozempic patent in India, health experts warn about potential negative impacts. Who stands to lose the most?
As Novo Nordisk's patent on semaglutide, the active ingredient in Ozempic and Mounjaro, expires in India, low-cost generic versions are set to flood the market. While this increases accessibility for obesity and diabetes treatment, experts warn of potential misuse and health risks due to self-administration without medical supervision. Concerns over drug quality and proper storage also arise.
Mar 29, 2026
Eli Lilly Invests $2.75 Billion in AI-Driven Drug Development through Insilico Partnership | The Tech Buzz
Eli Lilly has entered a $2.75 billion partnership with Insilico Medicine to commercialize AI-discovered drugs, marking a significant investment in AI-driven drug discovery. The deal includes an immediate $115 million payment and grants Lilly global rights to develop multiple drug candidates identified through Insilico's machine learning platform, potentially revolutionizing the traditional drug development timeline.
Mar 29, 2026
Eli Lilly Enters $2.75 Billion Partnership with Insilico Medicine for AI-Driven Drug Development
Eli Lilly's stock (LLY) is projected to rise, with analysts maintaining a Buy rating and price targets of $1,281 from Truist and $1,250 from TD Cowen. This optimism follows favorable Phase 3 results for retatrutide in treating obesity and uncontrolled diabetes, which showed a 1.9% HbA1c reduction and 15.3% weight loss, outperforming Mounjaro.
Mar 29, 2026
Korea Aims to Develop Its Next Major Pharmaceutical Breakthrough Through a Startup - WOWTALE
South Korea's government is launching a "Full-Cycle Collaboration Plan for Pharma Biotech Venture Development" to support biotech startups in reaching global markets. The initiative, backed by the Ministry of SMEs and Startups and the Ministry of Health and Welfare, aims to enhance funding, partnerships, and commercialization support, addressing gaps in the biotech sector. Key players include Celltrion and Yuhan Corporation.
Mar 29, 2026
Immunophotonics Obtains European Patent for the Combined Use of Its Primary Asset...
Immunophotonics, Inc. announced the European Patent Office has granted a patent for its lead drug candidate, IP-001, which covers its use in combination with checkpoint inhibitors for treating solid tumors. This patent enhances the company's intellectual property portfolio and supports ongoing clinical trials, highlighting IP-001's potential to improve anti-tumor effects alongside existing therapies.
Mar 29, 2026
Roche Holding AG: A Reliable Pharmaceutical Leader with Underrated Stock and Strong Fundamentals...
Roche Holding AG, a leading Swiss pharmaceutical company, is trading at a discount despite a strong diagnostics push and promising drug pipeline. With significant revenue from North America and a reliable dividend, Roche's shares are seen as undervalued. Recent innovations, like the cobas eplex respiratory pathogen panel, enhance its diagnostics capabilities, while upcoming sales updates are anticipated by investors.
Mar 29, 2026
Delhi Police's ANTF Dismantles Inter-State Drug Syndicate; Seizes Alprazolam and Tramadol Valued at 4.5 Crore
Delhi Police's Anti-Narcotics Task Force has dismantled an inter-state drug cartel, seizing drugs worth ₹4.5 crore, including Alprazolam and Tramadol, from four accused. The operation highlights ongoing efforts to combat the illegal supply of psychotropic substances in the region.
Mar 29, 2026
GLP-1 Dronon Par India Mein Kadi Karwai! Generic Ki Badhotri Ke Beech Niyamak Ka Sakht Kadam
India's drug regulator, CDSCO, has intensified scrutiny on GLP-1 weight-loss drugs following the expiration of semaglutide patents, leading to over 40 companies launching generics. With prices dropping significantly, the regulator aims to curb unauthorized sales and misleading promotions. Major firms like Sun Pharma and Dr. Reddy's are entering the market, while compliance risks loom for non-adhering companies.
Mar 29, 2026
Government Dismisses Requirement for NAT Testing in Blood Banks Despite Collection of 14.6 Million Units
The Government of India has rejected the proposal to mandate Nucleic Acid Testing (NAT) for blood donations in both government and private blood banks, despite collecting 14.6 million units and ongoing transfusion risks.
Mar 29, 2026
As GLP-1 medications gain popularity, the patent for Ozempic lapses in India; health professionals caution about potential impacts.
Novo Nordisk's semaglutide, the active ingredient in Ozempic and Mounjaro, will see its patent expire in India, leading to a surge of affordable generic options. While this enhances access for obesity and diabetes treatment, experts warn of potential misuse and health risks without proper medical supervision. The Indian Ministry of Health emphasizes the need for prescriptions from qualified specialists to mitigate these concerns.
